NEW YORK (GenomeWeb News) – MDxHealth today announced it signed agreements with health insurance providers FedMed and America's Choice Provider Network, extending access to the company's ConfirmMDx prostate cancer test to 50 million additional lives.

FedMed has 40 million covered lives, while ACPN has 11.2 million lives, MDxHealth said. The firm said that more than 130 million covered lives now have access to the ConfirmMDx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.